Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

Thumbnail Image
Download
Name

Recurrent hormone-binding.pdf

Size

837.85 KB

Format

Adobe PDF

Checksum (MD5)

fd621d48fe1cdf56ad700739f2caa85f

Author(s)
Holst, Frederik
•
Hoivik, Erling A.
•
Taylor-Weiner, Amaro
•
Schumacher, Steven E.
•
Asmann, Yan W.
•
Grossmann, Patrick
•
Trovik, Jone
•
Necela, Brian M.
•
Thompson, E. Aubrey
•
Salvesen, Helga B.
more
Date Issued
May 2016
Journal
Scientific Reports
Publisher
Nature Publiashing Group
Citation
Holst, Frederik; Hoivik, Erling A.; Gibson, William J.; Taylor-Weiner, Amaro; Schumacher, Steven E. et al. “Recurrent Hormone-Binding Domain Truncated ESR1 Amplifications in Primary Endometrial Cancers Suggest Their Implication in Hormone Independent Growth.” Scientific Reports 6, 25521 (May 2016): 1-7 © 2016 Macmillan Publishers Limited, part of Springer Nature
Version
Final published version
Abstract
The estrogen receptor alpha (ERα) is highly expressed in both endometrial and breast cancers, and represents the most prevalent therapeutic target in breast cancer. However, anti-estrogen therapy has not been shown to be effective in endometrial cancer. Recently it has been shown that hormone-binding domain alterations of ERα in breast cancer contribute to acquired resistance to anti-estrogen therapy. In analyses of genomic data from The Cancer Genome Atlas (TCGA), we observe that endometrial carcinomas manifest recurrent ESR1 gene amplifications that truncate the hormone-binding domain encoding region of ESR1 and are associated with reduced mRNA expression of exons encoding the hormone-binding domain. These findings support a role for hormone-binding alterations of ERα in primary endometrial cancer, with potentially important therapeutic implications.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Broad Institute of MIT and Harvard
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution 4.0 International License
http://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/110377
DOI of Published Version
https://doi.org/10.1038/srep25521
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.